Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa

October 6, 2014 updated by: Michael Lowe
The purpose of this study will be to replicate previous findings of deficits in prefrontal activation during response inhibition tasks in bulimia nervosa and extend these findings by demonstrating similar deficiencies in activity during a functional behavioral task that requires the inhibition of eating. Findings from this study will potentially help to elucidate the underlying neural mechanisms of bulimia nervosa, and thus inform treatment and prevention efforts.

Study Overview

Status

Completed

Conditions

Detailed Description

Bulimia nervosa (BN), is a serious psychiatric disorder that has high rates of comorbidity and often results in role impairment for the suffer. Thus far, although psychosocial and behavioral risk factors and correlates of BN have been extensively researched, relatively few studies have focused on brain-based determinants of BN. Identification of neural mechanisms associated with self-regulatory control that may be integral in the development, maintenance, and prevention of this debilitating condition would better inform treatment development and eating disorder prevention efforts.

Participation in this study consists of a 3-3.5 hours study visit as well a a one year follow up visit. The first portion of initial study visit is part of the screening process, in which individuals will complete several questionnaires and be interviewed by the study researcher in order to confirm eligibility. If a participant is eligible after the screening portion, they move onto the rest of the initial visit. During the initial visit, participants will complete a button pressing go/no-go task as well as a sipping go/no-go task, all while wearing a functional near-infrared spectroscopy (fNIR) device.

At a one year follow up appointment, individuals will again complete a variety of self-report questionnaires and be interviewed by the study researcher, thus completing the same measures used as screening tools in the initial visit.

Study Type

Observational

Enrollment (Actual)

47

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19102
        • Drexel University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women (ages 18-45 years) with bulimia nervosa and age, BMI, and IQ-matched controls.

Description

Inclusion Criteria:

  • Female
  • Right-handed
  • Age 18-45
  • Between 85 and 120% of ideal body weight based on height
  • Currently meeting proposed DSM-5 criteria for Bulimia Nervosa (at least one objective bulimic episode and compensatory purging episode per week for the past three months)
  • Purging via self-induced vomiting
  • Duration of illness of at least 6 months

Exclusion Criteria:

  • Current significant medical illness
  • Any disorder or condition resulting in difficulty swallowing (e.g., dysphagia)
  • History of neurological disorders or diseases (e.g., stroke, seizures, heart disease, head trauma with loss of consciousness)
  • Drug or alcohol abuse in the past 6 months or any history of alcohol or drug dependence
  • Use of marijuana or any other illegal drug (e.g., cocaine, heroin, ecstasy) in the week before the study visit
  • IQ less than 75
  • Pregnancy, lactation, or planning to become pregnant in the next year
  • Allergy to sucrose, dairy, wheat, gluten, apples (i.e., any of the ingredients in the strawberry yogurt shake or in the standardized meal prior to study participation)
  • Participants rating the strawberry yogurt shake as a 5 or lower on a 9-point category scale of liking will be excluded from further study
  • Meeting the criteria for a diagnosis of Attention Deficit Hyperactivity Disorder
  • Any other current major Axis I disorder, other than major depressive disorder (MDD) or generalized anxiety disorder (GAD)
  • Inability to consent
  • Prisoner

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Women with Bulimia Nervosa

fNIR

- Functional near-infrared spectroscopy measured-brain activity

Healthy Controls

fNIR

- Functional near-infrared spectroscopy measured-brain activity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Functional near-infrared spectroscopy
Time Frame: Day 1
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass index
Time Frame: Day 1 and 1 year
Body mass index, calculated from height and weight measurements
Day 1 and 1 year
Eating disorder examination (EDE)
Time Frame: Day 1 and 1 Year
Used to assess eating disorder symptom frequency and severity, including binge eating episode frequency.
Day 1 and 1 Year
Wechsler Abbreviated Scale of Intelligence (WASI™)
Time Frame: Day 1
Day 1
Mini-International Neuropsychiatric Interview (MINI)
Time Frame: Day 1
Day 1
Button pressing go/no-go task
Time Frame: Day 1
Day 1
Go/no-go sipping task
Time Frame: Day 1
Day 1
Psychosocial self-report measures
Time Frame: Day 1 and 1 Year
Measures to be administered include: Power of Food Scale (PFS), Beck Anxiety Inventory (BAI), Center for Epidemiological Studies Depression Scale (CES-D), Barratt Impulsivity Scale, Version 11 (BIS), Eating Loss of Control Scale (ELOCS), Difficulties in Emotion Regulation Scale (DERS), and Behavioral Inhibition and Behavioral Activation (BIS/BAS) Scales
Day 1 and 1 Year
Positive and Negative Affect Schedule (PANAS)
Time Frame: Day 1
This measure will assess mood ratings before the participant completes the standard go/no-go task and the sipping go/no-go task
Day 1
Generalized Labeled Magnitude Scale (gLMS)
Time Frame: Day 1
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (ACTUAL)

September 1, 2014

Study Registration Dates

First Submitted

August 5, 2013

First Submitted That Met QC Criteria

August 30, 2013

First Posted (ESTIMATE)

September 5, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

October 7, 2014

Last Update Submitted That Met QC Criteria

October 6, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bulimia Nervosa

Subscribe